Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

December 2, 2014

Primary Completion Date

December 15, 2016

Study Completion Date

December 15, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Ipilimumab

Trial Locations (43)

2065

Local Institution, St Leonards

2076

Local Institution, Wahroonga

3050

Local Institution, Parkville

13273

Local Institution, Marseille

18107

Urologische Praxis, Rostock

20037

George Washington University Medical Center, Washington D.C.

20133

Local Institution, Milan

23230

Virginia Cancer Institute, Richmond

32207

Baptist Cancer Institute, Jacksonville

35042

Local Institution, Rennes

38801

North Mississippi Med Center, Tupelo

39120

Universitaetsklinikum Magdeburg, Magdeburg

41009

Local Institution, Seville

42103

Dgu Urologie, Wuppertal

44805

Local Institution, Saint-Herblain

46009

Local Institution, Valencia

46483

Urologische Gemeinschaftspraxis Dres Stammel U. Garcia, Wesel

52074

Universitaetsklinikum Aachen, Aachen

63011

Local Institution, Clermont-Ferrand

67214

Cancer Center Of Kansas, Wichita

68130

Nebraska Cancer Specialists, Omaha

68167

Universitaetsklinikum Mannheim, Mannheim

69120

Uniklinik Heidelberg, Heidelberg

77024

Texas Oncology, Houston

80131

Istituto Nazionale Tumori Fondazione Pascale, Napoli

81675

Klinikum rechts der Isar der TU, München

94115

San Francisco Oncology Associates, San Francisco

94805

Local Institution, Villejuif

95615

Local Institution, Marktredwitz

97062

Northwest Cancer Specialists, Pc, Tualatin

97213

Providence Portland Medical Center, Portland

2540364

Local Institution, Viña del Mar

15232-1305

University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh

Unknown

Local Institution, Recoleta

Local Institution, Santiago

Local Institution, Poitiers

07743

Universitaetsklinikum Jena, Jena

1081 HV

Local Institution, Amsterdam

08035

Local Institution, Barcelona

08908

Local Institution, Hospitalet de Llobregat - Barcelona

G12 0YN

Local Institution, Glasgow

NG5 1PB

Local Institution, Nottingham

GU2 7XX

Local Institution, Guildford

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02279862 - Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | Biotech Hunter | Biotech Hunter